Japan IP Court cancels Chugai antibody patents, citing routine Fc mutation as obvious
Japan’s Intellectual Property High Court invalidated two patents held by Chugai Pharmaceutical for bispecific antibody technology, finding that the claimed Fc-region amino acid substitutions were obvious to skilled researchers and could...To view the full article, register now.
Already a subscriber? Click here to view full article